Autotransfusion Devices Market by Product Type (On-Pump Transfusion Devices, Off-Pump Transfusion Devices), by End Users (Ambulatory Surgical Centers, Hospitals, Emergency Rooms, Nursing Homes, and Others), Global Opportunity Analysis and Industry Forecast, 2019–2027

Auto-transfusion Device Market Overview and Forecast 2027:

The global autotransfusion device market size was valued at $1,121.5 million in 2018 and is projected to reach $1,939.7 million by 2027, registering a CAGR of 6.5% from 2019 to 2027. North America accounted for the highest share in 2018 and is anticipated to maintain its lead in the global autotransfusion device market throughout the forecast period.

An autotransfusion device is a mechanical device that is used in the process of collecting and re-infusing blood lost from hemorrhage.  Different forms of autotransfusion devices include intra-operative, emergency, or post-operative salvage devices and hemodilution devices used to re-infuse a patient's own blood. Autotransfusion devices market is growing because of growing prevalence of orthopedics and cardiac surgery. Furthermore, as autotransfusion devices is continually witnessing innovation is boosting the growth of autotransfusion device market globally.

Driving Factors in Autotransfusion Devices Market:

The factor that contribute toward growth of the global autotransfusion device market include high occurrence of cardiac devices contribute to the growth of autotransfusion device market globally. Furthermore, absence of any risk of transfusion or transmitted devices is a major factor that fuels the growth of the autotransfusion devices market. Moreover, absence of risk of alloimunization to blood cell boosts the growth of the autotransfusion devices market. However, inability to separate contaminations from blood cell is anticipated to hinder the growth of the autotransfusion Devices market. Conversely, growing adoption of full body transfusion devices is expected to offer lucrative opportunities during the forecast period.

Global Autotransfusion Device Market, by Product Type

Source: Research Dive Analysis

Depending on product type the market is divided into on pump transfusion devices and off pump transfusion devices.  Off pump transfusion devices has the highest market share and is expected to grow with the a CAGR of 6.6% during the forecast period owing to ease in use coupled with the fact that there’s no loss of blood during transfusion and it is considered safer than the conventional method.

Global Autotransfusion Device Market, by End-User

Source: Research Dive Analysis

By End User, autotransfusion device market is categorized into Ambulatory Surgical Centers, Hospitals, Emergency Rooms, Nursing Homes, and others. Hospital segment contributes the most among the end user segment. This is driven by the fact that hospitals have various specialized departments wherein blood transfusion is required as such the autotransfusion devices are required in multiple numbers to cater to various transfusion requirements of specialized symptoms coupled with the Guidelines set by the American Association of Blood Banks, the blood should be re-infused within 4 hours for washing is driving the growth of autotransfusion devices globally.

Regional Growth of Global Autotransfusion Device Market

Source: Research Dive Analysis

Geographically, the global market is segmented into North America, Europe, Asia-Pacific, and LAMEA. 
North America Autotransfusion Device Market Overview:
North American market is projected to reach $884.4 million by 2026, increasing at a CAGR of 6.4%, followed by the Europe market.

Top Key Players in Global Autotransfusion Device Market:

Some of the autotransfusion device companies include Medtronic Plc, Becton Dickinson and Company, Zimmer Biomet Holding, Teleflex Incorporated, LivaNova, Plc, Fresenius Medical Care AG & Co. KGaA, Stryker Corporation, Haemonetics Corporation, Terumo Corporation and Getinge AB. To gain competitive advantage the companies are looking to increase their reach through acquisitions. For example –October 2019, Medtronics Acquired AV Medical Technologies that operates as a medical devices company. Similarly, Getinge acquired Applikon Biotechnology, A world leader in developing and supplying advanced bioreactor systems from laboratory scale to production scale in December 2019.

Global Autotransfusion Device Market Trends

High Occurrence of Cardiac Diseases Leads to the Huge Demand of Auto-Transfusion devices across the world

With the improvement of medical technology and the growing discrepancy between blood supply and demand, autologous blood transfusion (ABT) has attracted more attention in recent years; its safety and effectiveness has gradually become a subject of interest. ABT can avoid the serious harm caused by allogeneic blood transfusion, alleviate blood shortage and save blood resources, while lightening the burden of patients. Therefore, ABT has gained more attention, has become a common demand in clinical practice, and is becoming widely used clinically. Increased adoption of technologically advanced autotransfusion devices is stimulating the growth of autotransfusion devices market.

Absence of any risk of transfusion & transmitted infections

The risk of transmission of infectious diseases (hepatitis, malaria, AIDS etc.) is eliminated; there is no danger of isosensitization; autologous blood ensures a better oxygen transfer and higher activity of coagulation factors; pretransfusion examinations are eliminated; there is no need to postpone the operation for shortage of blood; the consumption of homologous blood is reduced; economy; religious objections against transfusion of homologous blood are eliminated. There are no disadvantages of autotransfusion. Blood for autotransfusion was collected from patients before a planned operation; multiple times two consecutive blood collections were made. No complication threatening the patient's health was encountered.

The exceptional increase in popularity of autotransfusion has certainly been due to the worldwide explosion of the AIDS pandemics, and to the diffusion within the general public of new critical appreciation of all medical procedures, and of blood transfusion in particular.

Inability to Separate Contaminants from Blood is Expected To Be A Major Restraint for Autotransfusion Devices Market

A major disadvantage is the inability of these machines to separate contaminants from blood without the removal and discard of blood elements other than the red blood cells. The beneficial blood elements which are removed include platelets and proteins, such as the clotting factors and albumin. The removal of these components from blood can be responsible for a dilutional coagulopathy when blood loss is high. Thus, this can act as a restraint to the growth of autotransfusion devices.

Expensive Autotransfusion System

Another significant disadvantage to such systems is the cost. The hardware required to process the blood is complicated and can cost $40,000 or more. The disposable software is also not inexpensive. Additionally, a trained, dedicated technician is required to run the equipment. Maintaining availability of autotransfusion with processing during second and third shift and weekends can be a serious scheduling problem. These drawbacks have caused a number of doctors to explore alternatives to cell processing. These clinicians point out that the need to centrifuge has not been proven and, when the blood is not contaminated, many consider processing to be a costly and often unnecessary step that removes beneficial elements

Growing Adoption of whole body autotransfusion devices

The benefits of whole blood intraoperative autotransfusion are numerous. The patient benefits because platelets and proteins, such as albumin and clotting factors are returned along with the oxygen carrying red blood cells. There is no delay in returning the blood to the patient due to a time consuming processing step. Moreover, a scheduling system for cell processors is not needed because whole blood systems are immediately available and time for setup is minimal. Such clear benefits to the patient and hospitals have created significant recent interest in whole blood autotransfusion. Thus, this is expected to be creating opportunity for the growth of Autotransfusion devices as autotransfusion are now used for whole body transfusion enabling reduction in time and cost.